financetom
Business
financetom
/
Business
/
Cintas' Fiscal Q3 Earnings, Revenue Rise; Raises Fiscal 2025 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cintas' Fiscal Q3 Earnings, Revenue Rise; Raises Fiscal 2025 Guidance
Mar 26, 2025 6:22 AM

08:50 AM EDT, 03/26/2025 (MT Newswires) -- Cintas ( CTAS ) reported fiscal Q3 earnings Wednesday of $1.13 per diluted share, up from $0.96 a year earlier.

Analysts polled by FactSet expected $1.06.

Revenue for the quarter ended Feb. 28 was $2.61 billion compared with $2.41 billion a year earlier.

Analysts surveyed by FactSet expected $2.60 billion.

The company raised its fiscal 2025 earnings guidance to $4.36 to $4.40 per diluted share from $4.28 to $4.34. Analysts polled by FactSet expect $4.31. The company also increased the lower end of its revenue guidance to $10.28 billion to $10.31 billion from $10.26 billion to $10.32 billion. Analysts polled by FactSet expect $10.29 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ImmunityBio Says Anktiva Therapy Prolonged Overall Survival in Phase 2 Non-Small Cell Lung Cancer Study
ImmunityBio Says Anktiva Therapy Prolonged Overall Survival in Phase 2 Non-Small Cell Lung Cancer Study
Sep 8, 2025
09:27 AM EDT, 09/08/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday that results from its phase 2 study showed Anktiva therapy reverses lymphopenia and prolongs overall survival in patients with advanced non-small cell lung cancer. Lymphopenia is an adverse effect associated with chemotherapy, radiotherapy, and immunotherapy, and it lowers overall survival rates in various types of cancer, the...
DuPont secures 10-year US import ban on China's Dawnsens in Tyvek case
DuPont secures 10-year US import ban on China's Dawnsens in Tyvek case
Sep 8, 2025
Sept 8 (Reuters) - DuPont ( DD ) said on Monday China's Dawnsens New-Materials will not sell or import products tied to the chemical company's Tyvek brand in the U.S. for 10 years, as part of a trade secrets dispute resolution. The International Trade Commission approved Dawnsens', also known as Dangs, voluntary agreement to the consent order. The ban, effective...
Bath & Body Works to Hire Over 30,000 Seasonal Workers Ahead of Holidays
Bath & Body Works to Hire Over 30,000 Seasonal Workers Ahead of Holidays
Sep 8, 2025
09:29 AM EDT, 09/08/2025 (MT Newswires) -- Bath & Body Works ( BBWI ) said Monday it plans to hire 30,000 seasonal associates across the US, Canada, and Puerto Rico to meet the expected surge in demand during the holiday season. Roles include part-time seasonal associates to support nearly 1,900 stores and over 2,000 full-time merchandise processors, handlers, outbound loaders...
Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year
Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year
Sep 8, 2025
Rapport Therapeutics, Inc. ( RAPP ) stock traded higher on Monday, with a session volume of 3.20 million compared to the average volume of 179.3 thousand, according to data from Benzinga Pro. On Monday, the company revealed data from the Phase 2a trial of RAP-219 (RAP-219-FOS-201) in patients with drug-resistant focal onset seizures. The study met its primary endpoint, demonstrating...
Copyright 2023-2026 - www.financetom.com All Rights Reserved